MINJUVI®(tafasitamab) provisionally approved by Therapeutic Goods Administration[1]
Recent five-year follow-up data from Phase 2 L-MIND investigation showed patients treated with MINJUVI had prolonged, durable responses[2]
Read more at prnewswire.com